CN1523987A - 治疗牙周疾病的免疫反应调节剂 - Google Patents

治疗牙周疾病的免疫反应调节剂 Download PDF

Info

Publication number
CN1523987A
CN1523987A CNA028118715A CN02811871A CN1523987A CN 1523987 A CN1523987 A CN 1523987A CN A028118715 A CNA028118715 A CN A028118715A CN 02811871 A CN02811871 A CN 02811871A CN 1523987 A CN1523987 A CN 1523987A
Authority
CN
China
Prior art keywords
alkyl
use according
immune response
carbon atoms
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028118715A
Other languages
English (en)
Chinese (zh)
Inventor
苏米塔・B・米特拉
苏米塔·B·米特拉
・E・塞尔伯恩
查尔斯·E·塞尔伯恩
A・托迈
马克·A·托迈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of CN1523987A publication Critical patent/CN1523987A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028118715A 2001-06-15 2002-06-14 治疗牙周疾病的免疫反应调节剂 Pending CN1523987A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29876801P 2001-06-15 2001-06-15
US60/298,768 2001-06-15

Publications (1)

Publication Number Publication Date
CN1523987A true CN1523987A (zh) 2004-08-25

Family

ID=23151928

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028118715A Pending CN1523987A (zh) 2001-06-15 2002-06-14 治疗牙周疾病的免疫反应调节剂

Country Status (5)

Country Link
EP (1) EP1401437A1 (https=)
JP (1) JP2005519849A (https=)
CN (1) CN1523987A (https=)
CA (1) CA2449754A1 (https=)
WO (1) WO2002102377A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114616234A (zh) * 2019-02-07 2022-06-10 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
RU2327460C2 (ru) 2001-11-29 2008-06-27 3М Инновейтив Пропертиз Компани Фармацевтические составы, содержащие иммуномодулятор
CA2365732A1 (en) 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
NZ534566A (en) 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
MXPA04012199A (es) 2002-06-07 2005-02-25 3M Innovative Properties Co Imidazopiridinas sustituidas con eter.
NZ538812A (en) 2002-08-15 2009-02-28 3M Innovative Properties Co Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (ja) 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー １ｈ−イミダゾダイマー
MXPA05006740A (es) 2002-12-20 2005-10-05 3M Innovative Properties Co Imidazoquinolinas arilo-sustituidas.
AU2003300184B8 (en) 2002-12-30 2009-12-03 3M Innovative Properties Company Immunostimulatory combinations
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
MXPA05009694A (es) 2003-03-13 2005-10-20 3M Innovative Properties Co Metodos para mejorar la calidad de la piel.
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
AU2004244962A1 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
MXPA06002199A (es) 2003-08-27 2006-05-22 3M Innovative Properties Co Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi.
JP2007504172A (ja) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
WO2005051317A2 (en) 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
US8940755B2 (en) 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
WO2010080345A1 (en) 2008-12-19 2010-07-15 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
EA025993B1 (ru) 2009-07-13 2017-02-28 Медисис Фармасьютикал Корпорейшн Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
WO2019216438A1 (ja) * 2018-05-11 2019-11-14 株式会社セルテクノロジー 間葉系細胞の培養上清を含む歯周病治療剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420168D0 (en) * 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
US6541485B1 (en) * 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
MXPA03000388A (es) * 2000-07-13 2003-09-25 Alteon Inc Metodo para tratar enfermedades fibroticas u otras indicaciones ic.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114616234A (zh) * 2019-02-07 2022-06-10 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用
CN114616234B (zh) * 2019-02-07 2024-04-12 康威(广州)生物科技有限公司 磷咪唑并喹啉胺衍生物、及其药物组合物和应用

Also Published As

Publication number Publication date
CA2449754A1 (en) 2002-12-27
JP2005519849A (ja) 2005-07-07
WO2002102377A1 (en) 2002-12-27
EP1401437A1 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
CN1523987A (zh) 治疗牙周疾病的免疫反应调节剂
CN1103219C (zh) 含有透明质酸的制剂
CN1235559C (zh) 皮肤水分保持能力的改善剂
US7226928B2 (en) Methods for the treatment of periodontal disease
CN100346788C (zh) 用于鼻内给药的芬太尼组合物
CN1212841C (zh) 减轻阿扑吗啡的副作用
CN1242813C (zh) 骨质疏松症的联合疗法
CN1248734C (zh) 用于伤口愈合的基质蛋白组合物
CN1196473C (zh) 油性佐剂疫苗及其制备方法
CN1610550A (zh) 包括免疫反应改性剂的药物制剂
CN1882353A (zh) 催涎剂和混合该催涎剂的口腔用组合物以及食品组合物
CN1044047A (zh) 抗蚀斑抗菌口用复方
CN1561389A (zh) 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
CN1684683A (zh) Hcv丝氨酸蛋白酶的有效抑制剂
CN1946392A (zh) 含有单乙酰基二酰基甘油衍生物的免疫调节剂、抗癌剂和健康食品
CN1826127A (zh) 用于促进热休克蛋白合成的一种含有以富含羽扇醇的提取物为活性成分的化妆品或药学组合物的用途
Gonçalves et al. MMP13, TIMP2 and TGFB3 gene polymorphisms in Brazilian chronic periodontitis and periimplantitis subjects
CN1674930A (zh) 包含组合物的酶,所述组合物的生产工艺及其用途
CN1192234A (zh) 龋齿的替补疗法
CN1708312A (zh) 新的天然来源的葡萄糖苷酶抑制剂
CN1620301A (zh) 医药上可接受的带有磷酸盐－甘油的主体
CN1525858A (zh) 包括调节胆碱能功能的烟碱性受体部分拮抗剂与止吐药的药物组合物
Cury et al. Evaluation of the effect of tumor necrosis factor-alpha gene polymorphism on the risk of peri-implantitis: a case-control study.
CN1535711A (zh) 治疗烧烫伤、皮肤粘膜溃疡的药物组合物
CN1069517C (zh) 口腔组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication